Abstract 1668P
Background
Significant progress has been made in the management of PDAC in recent years, with the development of new chemotherapy regimens validated in both adjuvant and metastatic settings, as well as neoadjuvant/induction therapy (N/IT). In this population-based study, we aimed to compare prevalence, therapeutic strategies, and survival outcomes of PDAC patients in France over a decade encompassing these advances.
Methods
This study was performed on SNDS (Système National des Données de Santé) data, including nationwide French data on the consumption of medical care. All patients managed for PDAC during years 2009, 2014 and 2018 were included. Treatment modalities and survival outcomes were analyzed.
Results
A total of 8143/10267/12089 patients were included during years 2009/2014/2018, respectively. Prevalence increased mainly among patients aged 60-75 (62% over the study period) and >75 (53%) while a lesser trend was seen in patients <60 (13%). In localized PDAC, the proportion of patients receiving best supportive care (BSC) decreased at 43.6/37.7/33.5%. More patients received chemotherapy +/- radiotherapy alone over time (27.8/28.5/33.4%), and surgical resection after N/IT increased at 0.9/2.5/5.5%. The rate of upfront surgery remained stable at about 28%. Among metastatic patients, 45.0/49.2/51.3% received BSC. In the overall population, no relevant difference in survival outcomes were seen over time, but median overall survival (OS) and 1-year OS improved significantly both in localized patients and treated metastatic patients (Table). The 1-year OS was 85.7/85.9/91.7% among patients receiving N/IT before surgery, vs 76.3/79.0/80.0% for upfront resection. Table: 1668P
Survival outcomes
Population | Median OS (months) / 1-year OS (%) | p-value log-rank | ||
2009 | 2014 | 2018 | ||
Overall | 7.0 / 36.1 | 6.9 / 36.9 | 7.5 / 39.4 | 0.0067 |
Localized | 11.4 / 48.4 | 12.5 / 51.3 | Not reached / 55.0 | <0.0001 |
Metastatic (treated) | 7.3 / 30.3 | 8.4 / 36.1 | 8.9 / 38.2 | <0.0001 |
Conclusions
This study confirms an increase in the prevalence of PDAC in France. Improved survival outcomes were seen in localized PDAC, with a wider use of chemotherapy and an increase in neo-adjuvant/induction strategies, and in treated metastatic patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ACOBIOM.
Funding
ACOBIOM.
Disclosure
L. Mas: Financial Interests, Personal, financially compensated role: Merck. J. Bachet: Financial Interests, Personal, Advisory Role: Amgen, AstraZeneca, Bayer, BMS, GSK, Merck, MSD, Pierre Fabre, Roche, Sanofi, Servier; Financial Interests, Personal, Non-financial benefits: Amgen, Merck, Roche, Servier. All other authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22